Situation with cancer care in Russia. Kidney cancer (median survival, cumulative survival, and survival of patients depending on their disease stage). Population-based study at the federal district level. Part 2

Background. In the first part of our study, we described the dynamics of kidney cancer (С64) incidence and mortality, as well as reliability of kidney cancer surveillance in Russia. This study analyzed the effectiveness of cancer control measures in Russia by assessing patient survival using the data form the newly developed Population-based cancer registry of the North-Western Federal District.

Materials and methods. We used the data from the Population-based cancer registry of the North-Western Federal District of Russia that has more than 1,350,000 records, including 35,629 kidney cancer patients. Standard methods of the European Network of Cancer Registries (EUROCARE program) were used for data processing and analysis.

Results. Our findings confirmed that kidney cancer is characterized by a low death rate. Over the last 18 years, median survival of kidney cancer patients in the North-Western Federal District of Russia increased form 4 years to 6.5 years. The 1-year survival rate increased from 68 % to 78.5 % (by 16.5 %); 5-year cumulative observed survival increased from 47.3 % to 54.1 %; 5-year cumulative relative survival increased from 56.8 % to 61.8 %. Female kidney cancer patients demonstrated higher 5-year cumulative survival rates than male patients (65.8 % vs 43.9 %).

Conclusion. We observed a positive dynamic of the main analytical indicators of cancer control, including an increase in the median survival and 5-year cumulative survival of kidney cancer patients.

1. Merabishvili V.M. Survival of cancer patients. Issue 2. Part I. Saint Petersburg: KOSTA, 2011. 330 p. (In Russ.)

2. Merabishvili V.M. Survival of cancer patients. Issue 2. Part II. Saint Petersburg: KOSTA, 2011. 408 p. (In Russ.)

3. Merabishvili V.M., Manikhas G.M. Malignant kidney tumors. Incidence, mortality, analytical parameters, and survival. Outpatient oncology: new opportunities. Proceedings of the international conference. 12–13 October 2017. Saint Petersburg: Gippokrat, 2017. P. 10–13. (In Russ.)

4. Malignant tumors in Russia in 2005 (incidence and mortality). Eds.: V.I. Chissov, V.V. Starinskiy, G.V. Petrova. Moscow: FGU MNIOI im. P.A. Gertsena Roszdrava, 2007. Рр. 232–249. (In Russ.).

5. Berezkin D.P. Methods of studying survival in cancer patients. Methodical guideline. Leningrad, 1982. 24 p. (In Russ.).

6. Merabishvili V.M. Malignant tumors in the North‑West Federal Region of Russia (morbidity, mortality, index accuracy, survival). Express‑information. Issue 5. Eds.: A.M. Belyaev, A.M. Shcherbakov. Saint Petersburg: T8 Izdatel’skie tekhnologii, 2020. 236 p. (In Russ.).

7. Napalkov N.P., Berezkin D.P. Principles and methods of studying survival in cancer patients. Voprosy onkologii = Problems in Oncology 1982;28(8):10–3. (In Russ.).

8. Organization and use of the populationbased cancer registry. Methodical guideline. Ed.: A.V. Eliseeva. Moscow, 2001. 14 p. (In Russ.).

9. Characteristics and methods of calculating statistical parameters used in oncology. Practical guide. Ed.: A.V. Eliseeva. Moscow, 2005. 43 p. (In Russ.).

10. Merabishvili V.M., Poltorackiy A.N., Nosov A.K. et al. The state of oncology care in Russia. Kidney cancer (morbidity, mortality, index of accuracy, one‑year and year‑by‑year mortality, histological structure). Part 1. Onkourologiya = Cancer Urology 2021;17(2):182–94. (In Russ.). DOI: 10.17650/1726‑9776‑2021‑17‑2‑182‑194

11. Berrino F., Sant M., Verdecchia V. et al. Survival of cancer patients in Europe: the EUROCARE Study (IARC Scientific Publications No. 132). Lyon: International Agency for Research on Cancer, 1995.

12. Berrino F., Capocaccia R., Coleman M.P. et al. Survival of cancer patients in Europe: the EUROCARE‑2 study (IARC Scientific Publications No. 151). Lyon: International Agency for Research on Cancer, 1999.

13. Sant M., Aareleid T., Berrino F. et al. EUROCARE‑3: the survival of cancer patients diagnosed in Europe during 1990– 94. Ann Oncol 2003;14(Suppl 5):v61–118. DOI: 10.1093/annonc/mdg754

14. Gatta G., Zigon G., Capocaccia R. et al. Survival of cancer patients in Europe, 1995–2002. Eur J Cancer 2009;45(6):992– 1005. DOI: 10.1016/j.ejca.2008.11.042

15. De Angelis R., Sant M., Coleman M.P. et al. Cancer survival in Europe 1999– 2007 by country and age: results of EUROCARE‑5 – a population‑based study. Lancet Oncol 2014;15(1):23–34. DOI: 10.1016/S1470‑2045(13)70546‑1

16. Gatta G., Botta L., Rossi S. et al. Childhood cancer survival in Europe 1997–2007: results of EUROCARE‑5 – a population‑based study. Lancet Oncol 2014;15(1):35–47. DOI: 10.1016/S1470‑2045(13)70548‑5

17. Merabishvili V.M. Medical and statistical glossary. Methodical manual for doctors, residents, postgraduates, and researchers. Issue 2. Saint Petersburg, 2020. 145 р. (In Russ.).

18. Merabishvili V.M. Malignant tumors in the North‑West Federal Region of Russia (morbidity, mortality, prevalence rate, survival). Express‑information. Issue 4. Ed.: A.M. Belyaev. Saint Petersburg: T8 Izdatel’skie tekhnologii, 2018. 444 p. (In Russ.).

19. Malignant tumors in Russia in 2018 (morbidity and mortality). Eds.: А.D. Kaprin, V.V. Starinskiy, G.V. Petrova. Moscow: MNIOI im. P.A. Gertsena – filial FGBU “NMITS radiologii” Minzdrava Rossii, 2019. 250 p. (In Russ.).

20. Merabishvili V.M. Malignant tumors in the North‑Western Federal District of Russia. Issue 2. Ed.: A.M. Belyaev. Saint Petersburg: Ladoga, 2015. 556 p. (In Russ.).

21. State of oncological care in Russia in 2019. Eds.: А.D. Kaprin, V.V. Starinskiy, A.O. Shachzadova. Moscow: MNIOI im. P.A. Gertsena – filial FGBU “NMITS radiologii” Minzdrava Rossii, 2020. 239 p. (In Russ.).